Free Trial

Xilio Therapeutics (XLO) Competitors

Xilio Therapeutics logo
$0.76 +0.00 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 +0.00 (+0.08%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XLO vs. ELDN, CCCC, THTX, PEPG, MOLN, NKTX, ANRO, NVCT, CRDF, and ACOG

Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), Nkarta (NKTX), Alto Neuroscience (ANRO), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

Xilio Therapeutics vs. Its Competitors

Eledon Pharmaceuticals (NASDAQ:ELDN) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Eledon Pharmaceuticals has higher earnings, but lower revenue than Xilio Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.98
Xilio Therapeutics$15.00M2.61-$58.24M-$0.76-0.99

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.27 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eledon Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Eledon Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Eledon Pharmaceuticals' return on equity of -92.51% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -92.51% -38.31%
Xilio Therapeutics -374.79%-399.15%-58.68%

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 186.53%. Xilio Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 297.14%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Eledon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Xilio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Eledon Pharmaceuticals beats Xilio Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XLO vs. The Competition

MetricXilio TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$39.15M$3.43B$6.11B$10.62B
Dividend YieldN/A2.27%5.72%4.85%
P/E Ratio-0.9923.2429.2227.30
Price / Sales2.61270.27491.88184.03
Price / CashN/A45.2825.8230.35
Price / Book1.8910.6612.476.65
Net Income-$58.24M-$52.56M$3.32B$276.14M
7 Day Performance-0.47%4.97%1.87%0.01%
1 Month Performance-3.15%16.48%8.40%3.60%
1 Year Performance-6.65%14.95%63.49%32.74%

Xilio Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XLO
Xilio Therapeutics
1.5353 of 5 stars
$0.76
+0.2%
$3.00
+297.1%
-3.2%$39.15M$15.00M-0.9970Gap Up
ELDN
Eledon Pharmaceuticals
1.8385 of 5 stars
$2.72
-0.7%
$10.00
+267.6%
+17.8%$164.08MN/A-2.3210Gap Up
CCCC
C4 Therapeutics
3.5843 of 5 stars
$2.11
-6.2%
$8.50
+302.8%
-60.0%$160.13M$35.58M-1.34150News Coverage
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+157.1%$157.21M$84.38M-17.99140High Trading Volume
PEPG
PepGen
3.2039 of 5 stars
$4.55
-3.6%
$8.40
+84.6%
-44.6%$154.65MN/A-1.5430
MOLN
Molecular Partners
1.3739 of 5 stars
$3.87
+1.7%
$8.00
+107.0%
-24.5%$153.42M$5.65M-1.86180Gap Down
NKTX
Nkarta
2.472 of 5 stars
$2.26
+4.6%
$13.50
+497.3%
-42.7%$153.41MN/A-1.53140Gap Down
ANRO
Alto Neuroscience
1.2748 of 5 stars
$5.89
+4.5%
$9.80
+66.3%
-23.4%$152.71MN/A-2.47N/ATrending News
Analyst Forecast
NVCT
Nuvectis Pharma
2.5969 of 5 stars
$6.19
+3.9%
$15.33
+147.7%
-18.4%$151.72MN/A-5.298
CRDF
Cardiff Oncology
1.8897 of 5 stars
$2.26
+2.3%
$10.63
+370.1%
-21.4%$147.02M$680K-2.6020Positive News
ACOG
Alpha Cognition
2.4957 of 5 stars
$7.05
+0.4%
$20.00
+183.7%
N/A$146.73MN/A-4.41N/ANews Coverage
Analyst Downgrade
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:XLO) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners